KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average: 2017-2024

Historic Equity Average for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to -$44.8 million.

  • Amneal Pharmaceuticals' Equity Average fell 47.29% to -$111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$111.2 million, marking a year-over-year decrease of 47.29%. This contributed to the annual value of -$44.8 million for FY2024, which is 143.88% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' Equity Average stood at -$44.8 million, which was down 143.88% from $102.0 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Equity Average peaked at $356.0 million during FY2021, and registered a low of -$44.8 million during FY2024.
  • Over the past 3 years, Amneal Pharmaceuticals' median Equity Average value was $102.0 million (recorded in 2023), while the average stood at $110.9 million.
  • In the last 5 years, Amneal Pharmaceuticals' Equity Average increased by 2.92% in 2021 and then plummeted by 143.88% in 2024.
  • Amneal Pharmaceuticals' Equity Average (Yearly) stood at $345.9 million in 2020, then climbed by 2.92% to $356.0 million in 2021, then declined by 22.61% to $275.5 million in 2022, then crashed by 62.97% to $102.0 million in 2023, then slumped by 143.88% to -$44.8 million in 2024.